BioAdvance

BioAdvance Capital is an early-stage life sciences venture capital firm dedicated to improving human health by investing in transformative companies. The firm focuses on a broad range of sectors within life sciences, including therapeutics, medical devices, digital health, diagnostics, and research tools. As an evergreen fund, BioAdvance maintains a long-term investment perspective, providing crucial early-stage funding to empower companies to develop groundbreaking health technologies and attract substantial follow-on investments.

Established in 2002, BioAdvance was founded to address the critical funding needs of emerging human life science companies, particularly within the Mid-Atlantic region of the United States. The firm's mission-driven approach emphasizes supporting innovators who are committed to developing technologies with the potential to significantly impact human well-being and quality of life. Their strategic investments aim to help companies reach critical de-risking or value-inflection points, enhancing their appeal to larger venture capital firms, corporate partners, or other funding sources.

BioAdvance has built a robust portfolio of over 120 companies, which collectively have attracted more than $4.4 billion in external capital to support their growth. Notable portfolio companies include Latus Bio, which recently secured significant Series A financing for gene therapy, and others like ImmunoGenesis, Strados Labs, and Keriton, demonstrating the firm's commitment to fostering innovation across various life science sub-sectors. The firm's investments have also led to 12 products receiving FDA approval and 28 exits across all sectors.

The BioAdvance team comprises experienced investment experts and strategists, including successful investors, seasoned entrepreneurs, skilled medical professionals, and leading life science experts. Key team members like Managing Director & CEO Shahram Hejazi, Ph.D., and Partner Gregory Harriman, M.D., bring extensive industry expertise in areas ranging from R&D and global operations to clinical development and regulatory submissions. This diverse background enables the team to identify high-potential ventures, provide strategic guidance, and collaborate closely with entrepreneurs to navigate the complex path from concept to market, ensuring capital efficiency and a focus on human health outcomes.